Searching for new TCR targets, immunotherapy startup emerges with Stanford tech, $40M round
25 Aug 2022
Cell TherapyVaccineImmunotherapy
In the last decade, immunotherapy, which involves the usage of a patient’s own immune cells to fight cancers, has gained great momentum. In one variation, the treatment involves removing a patient’s T cells, a type of white blood cell, and enabling them to recognize proteins that are only present in cancer cells. Upon finding its nemesis the T cells attack the cancer cells. But the major challenge researchers face is discovering more and more of these proteins that are displayed specifically on cancer cells, said Stefan Scherer, CEO of 3T Biosciences, a San Francisco-based biotech.
“To identify novel targets is not trivial,” he added.
His company has developed an AI-based platform to identify novel targets and announced Thursday morning it has raised $40 million in Series A funding. The round was led by Westlake Village BioPartners with participation from Lightspeed Venture Partners.
In addition to cell therapies, the company believes its targets can lead to new bispecifics and peptide vaccines. To that end, it’s also developing a technique to find new peptides — or binders — that hook to the cancer proteins at one end and T cells on the other hand.
“The problem is peptides which are currently used in immunotherapy is that sometimes [they] closely represent what is present in human peptides and you see unspecific binding to noncancer cells, which leads to side effects,” said Scherer.
“That way the risk that the peptide binds to a receptor randomly in the gut, in the eye, in the brain is not there,” he added.
In the last five years, the team identified more than a dozen target proteins on cancer cells from colon cancer to breast cancers. The new funding will go toward bringing a couple of them to the clinical stage.
“We will apply for investigational new drug next year and hope to bring our first target into the clinic in 2023 or early 2024,” said Scherer.
The company was founded in 2017 by Leah Sibener and Marvin Gee, who finished their PhDs at Chris Garcia’s lab at Stanford University. Their company exclusively in-licensed the technology from the university.
3T is not alone in its pursuits. Longwood has backed a number of startups promising to unearth new ways to unlock immuno-oncology, including Pyxis and Immunitas. This month, New York-based Envisagenics announced that it was awarded a $2 million Small Business Innovation Research Direct to Phase II grant from the National Cancer InstituteCancer Institute to commercialize its proprietary drug discovery platform, SpliceIOTM, for the discovery of new I/O targets.
3T’s investors however believe that the company is entering a space where multiple players can contribute. “3T Biosciences’ technology enables us to address one of the biggest challenges in cancer treatment – developing next-generation therapies for solid tumors and other immune-mediated diseases with curative potential,” said Sean Harper, managing director at Westlake Village BioPartners.
“In addition, the 3T technology is of great interest to a large number of biopharma companies active in the oncology and autoimmune spaces,” he added.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.